Loading...
XNYSBLCO
Market cap6.28bUSD
Dec 23, Last price  
17.83USD
1D
-0.94%
1Q
-7.18%
IPO
-0.94%
Name

Bausch + Lomb Corp

Chart & Performance

D1W1MN
XNYS:BLCO chart
P/E
P/S
1.51
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
0.03%
Rev. gr., 5y
2.50%
Revenues
4.15b
+10.03%
3,665,000,0003,778,000,0003,412,000,0003,765,000,0003,768,000,0004,146,000,000
Net income
-260m
L
710,000,000298,000,000-17,000,000182,000,00015,000,000-260,000,000
CFO
-17m
L
763,000,000799,000,000522,000,000873,000,000345,000,000-17,000,000
Earnings
May 29, 2025

Profile

Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.
IPO date
May 06, 2022
Employees
13,000
Domiciled in
CA
Incorporated in
CA

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑12
Income
Revenues
4,146,000
10.03%
3,768,000
0.08%
3,765,000
10.35%
Cost of revenue
3,702,000
3,304,000
3,127,000
Unusual Expense (Income)
NOPBT
444,000
464,000
638,000
NOPBT Margin
10.71%
12.31%
16.95%
Operating Taxes
82,000
58,000
125,000
Tax Rate
18.47%
12.50%
19.59%
NOPAT
362,000
406,000
513,000
Net income
(260,000)
-1,833.33%
15,000
-91.76%
182,000
-1,170.59%
Dividends
Dividend yield
Proceeds from repurchase of equity
(10,000)
BB yield
0.17%
Debt
Debt current
30,000
25,000
20,000
Long-term debt
4,706,000
2,503,000
184,000
Deferred revenue
(92,000)
Other long-term liabilities
310,000
329,000
298,000
Net debt
4,405,000
2,162,000
30,000
Cash flow
Cash from operating activities
(17,000)
345,000
873,000
CAPEX
(181,000)
(175,000)
(209,000)
Cash from investing activities
(2,109,000)
(215,000)
(214,000)
Cash from financing activities
2,078,000
81,000
(712,000)
FCF
(78,000)
198,000
598,000
Balance
Cash
331,000
354,000
174,000
Long term investments
12,000
Excess cash
123,700
177,600
Stockholders' equity
(1,429,000)
(1,184,000)
9,402,000
Invested Capital
13,308,000
11,050,000
9,720,000
ROIC
2.97%
3.91%
5.13%
ROCE
3.73%
4.70%
6.55%
EV
Common stock shares outstanding
350,500
350,000
350,000
Price
17.06
9.99%
15.51
 
Market cap
5,979,530
10.15%
5,428,500
 
EV
10,454,530
7,658,500
EBITDA
826,000
843,000
1,053,000
EV/EBITDA
12.66
9.08
Interest
283,000
146,000
Interest/NOPBT
63.74%
31.47%